P-Values

Discover perspectives on the latest findings, biggest challenges and most exciting successes in our collective work.

At P-Values, you’ll find updates, perspective, insights and information from staff and partners working on the frontlines of research, advocacy and implementation. P-value is a statistical term for the probability that a trial result is reliable and not the outcome of chance. 

Featured

Blog Post

Global Health Watch: UNAIDS launches review, NIH GoF controversy, support for IDSA’s Jeanne Marrazzo, UK authorizes LEN for PrEP

This week the UNAIDS board approved a new Global AIDS Strategy and launched a formal review of the agency’s future; turmoil at the NIH continues over gain-of-function research; and the scientific community rallies around the Infectious Diseases Society of America’s (IDSA) appointment of Jeanne Marrazzo as its chief executive officer. Also, the UK regulatory agency approved lenacapavir for PrEP (LEN) marking its seventh regulatory approval in just six months.

Read more

Blog Post

Global Health Watch: NIH turmoil + a high-profile lawsuit, future of UNAIDS, more Countries sign “America First” MoUs with US

This week covers the significant turmoil at the US National Institutes of Health (NIH), including a close look at the NIH deputy director’s role in disruptions in leadership and funding cuts, and a lawsuit filed by the former Director of the National Institute of Allergy and Infectious Diseases (NIAID). It also covers urgent civil society pushback against efforts to sunset UNAIDS, the rapid expansion of US “America First” bilateral health agreements across Africa, and what’s next for STI research, prevention and diagnostics.

Read more

Filter by

Reset filters

P-Values

showing 1-10 of 1163

Global Health Watch: UNAIDS launches review, NIH GoF controversy, support for IDSA’s Jeanne Marrazzo, UK authorizes LEN for PrEP

This week the UNAIDS board approved a new Global AIDS Strategy and launched a formal review of the agency’s future; turmoil at the NIH continues over gain-of-function research; and the scientific community rallies around the Infectious Diseases Society of America’s (IDSA) appointment of Jeanne Marrazzo as its chief executive officer. Also, the UK regulatory agency approved lenacapavir for PrEP (LEN) marking its seventh regulatory approval in just six months.

Prevention Option:

Topic:

December 2025

30 Years of Standing for Science and Equity

This month, AVAC marked our 30th anniversary. Over three decades, the HIV field has evolved dramatically—but what we do, and why we do it, has remained constant: standing for science, equity, and community leadership, and ensuring evidence drives decisions that affect people’s lives. We’ve been able to do this work because of your partnership and support, and we are deeply grateful.

Prevention Option:

Topic:

December 2025

Global Health Watch: NIH turmoil + a high-profile lawsuit, future of UNAIDS, more Countries sign “America First” MoUs with US

This week covers the significant turmoil at the US National Institutes of Health (NIH), including a close look at the NIH deputy director’s role in disruptions in leadership and funding cuts, and a lawsuit filed by the former Director of the National Institute of Allergy and Infectious Diseases (NIAID). It also covers urgent civil society pushback against efforts to sunset UNAIDS, the rapid expansion of US “America First” bilateral health agreements across Africa, and what’s next for STI research, prevention and diagnostics.

Prevention Option:

Topic:

December 2025

AVAC Board Member Jeanne Marrazzo named CEO of IDSA 

AVAC enthusiastically applauds the selection of Jeanne Marrazzo, MD, to serve as the new chief executive officer of the Infectious Diseases Society of America (IDSA).

December 2025

The Future of HIV Prevention Depends on Speed, Scale and Equity 

We are in a golden moment, where innovation, evidence and opportunity align. But proposed funding cuts could undo everything. These aren’t abstract numbers on a page. These cuts would shutter clinics, slow prevention, restrict treatment, and roll back the very systems that allow new tools like LEN to reach people.

Prevention Option:

Topic:

December 2025

Global Health Watch: 4 African Countries Sign Bilateral Health MoUs with US, New People’s Research Agenda, Hepatitis B Vaccine Shift

This week covers fast-moving developments with new US bilateral Memos of Understanding (MoU) across Africa, including reactions from Kenya’s High Court, which suspended the agreement over the issue of sharing of health data, alongside new reporting on the adverse impact of US policy changes affecting science and research institutions, and a major reversal in US hepatitis B vaccine policy. We also track the newly updated People’s Research Agenda.

December 2025

Track the Science; Advance the Priorities

The People’s Research Agenda sets out a people-centered framework for equitable and accelerated R&D and product introduction. It tracks the science, shows where investments align—or fail to align—with community-defined priorities, and spotlights critical gaps in the pipeline of prevention options needed to meet the diverse realities of all populations.

December 2025

Global Health Watch: World AIDS Day advocacy, first injections of LEN for PrEP, CDC turmoil, Kenya signs US MoU

This week we track both momentum and mounting threats in the HIV response: powerful World AIDS Day advocacy even as the US refused to recognize it; first recipients of lenacapavir for PrEP in Brazil, Eswatini, South Africa and Zambia; continued CDC turmoil that threatens trust in vaccines and science-based public health; the US’ “New G20” without South Africa; and Kenya signs the first US global health Memo of Understanding (MoU).

December 2025

In the Midst of Chaos, a Historic Opportunity this World AIDS Day

World AIDS Day in 2025 comes at a moment of unprecedented change. Over 60 years of investment in global health, forty years of innovation and progress in the fight to end the HIV epidemic, and many of the critical programs that provide access to HIV prevention in high burden countries are in disarray and at risk of collapse. Yet, in the midst of the chaos, there’s a historic opportunity to defeat HIV by scaling-up the breakthrough technology of long-acting injectable PrEP.

December 2025

Global Health Watch: PEPFAR negotiations leave communities behind, Global Fund replenishment falls short, continued chaos at CDC and NIH

Decisions and actions this week further weaken the global HIV response — from the exclusion of communities in the new PEPFAR US global health strategy negotiations to a Global Fund replenishment that falls short. Major disruptions at the US CDC and NIH and the White House “skipping” World AIDS Day — continue the erosion of accountability, trust, and the integrity of the public health system.

Prevention Option:

Topic:

November 2025

showing 1-10 of 1163

Explore More News and Communications

P-Values Blog

Discover perspectives on the latest findings, biggest challenges and most exciting successes in our collective work.

Advocates Network

AVAC’s email list for organization and individuals interested in timely updates and critical perspectives on developments in biomedical HIV prevention.

Weekly News Digest

A comprehensive round-up of HIV prevention media coverage and scientific publications.

PxPulse

Each month this podcast uses interviews, discussion and first-person reflections to explore vital topics confronting the field of HIV prevention research.

PxWire

PxWire is AVAC’s quarterly update on biomedical HIV prevention. Each issue highlights key developments, challenges and opportunities, and features a centerspread infographic that provides a visual tool for framing these issues.

Pandemic Watch

Pandemic Watch is a curated news digest on the latest pandemic prevention, preparedness, and response (PPPR) news and resources.

Press Releases

A collection of official statements from AVAC.

AVAC in the News

Media clippings featuring AVAC, its staff and close partners in the news media.